Goodwin Advises Aureka Biotechnologies on Intellectual Property Aspects for $100 Million Series B

The Life Sciences team advised Aureka Biotechnologies with respect to IP matters and its underlying patent strategy on raising $100 million Series B to build a biological world model for drug discovery. Granite Asia exclusively funded the first tranche, and a prominent strategic investor led a subsequent tranche, with participation from HighLight Capital (HLC) and follow-on investment from existing shareholders including MPCi and NRL Capital. The financing brings Aureka’s total funding to nearly $200 million and will primarily support research and large-scale training of the company’s next generation of biological foundation models, as well as upgrades to its Lab-in-the-Loop experiment-centered feedback engine.

Aureka Biotechnologies is an AI-native TechBio company building next-generation biological foundation models and closed-loop AI-native infrastructure to transform the therapeutic discovery process. The company has raised nearly $200 million to date and established strategic partnerships with multiple leading global pharmaceutical companies to advance the development of novel antibody therapeutics. Aureka’s proprietary foundation model, AuraIDE, is trained on its internal protein co-evolution data and has demonstrated leading capabilities in protein folding and de novo design. Its open-source version, OpenDDE, ranks among the world’s leading open-source biomolecular models in independent third-party evaluations.

The Goodwin team was led by Matt Bresnahan, Matt Wheeler, and Claire Storey.

For more information on the deal, please read the press release.